XML 51 R44.htm IDEA: XBRL DOCUMENT v3.25.4
Collaborations - Additional Information (Details) - USD ($)
 1 Months Ended 3 Months Ended 12 Months Ended
Mar. 21, 2024
May 31, 2021
Mar. 31, 2019
Mar. 31, 2024
Dec. 31, 2025
Dec. 31, 2024
Dec. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Collaboration revenue         $ 7,695,000 $ 7,690,000  
Toray Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contract liabilities         820,000 905,000 $ 1,502,000
Variable consideration related to reimbursements for research and development services     $ 2,100,000        
Contract liability, current         300,000 400,000  
Contract liability, non-current         500,000 500,000  
Revenue         300,000 900  
Toray Agreement | Prepaid Expenses and Other Current Assets              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Research and development services receivables         45,000 7,500  
Genmab Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contract liabilities         1,173,000 5,730,000 6,664,000
Upfront payment received   $ 10,000,000          
Allocated from stock purchase agreement   1,400,000          
Variable consideration related to reimbursements for research and development services   12,400,000          
Contract liability, current         100,000 2,600,000  
Contract liability, non-current         1,100,000 3,100,000  
Collaboration revenue         7,400,000 3,300,000  
Potential future sale milestone payments   $ 160,000,000          
Genmab Agreement | Prepaid Expenses and Other Current Assets              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Research and development services receivables         600,000 800,000  
Genmab Agreement | Common Stock              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Common stock sold   41,052          
Consideration in excess of fair value   $ 1,400,000          
Purchase price under Stock Purchase Agreement   15,000,000          
Genmab Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Potential future sale milestone payments   $ 125,000,000          
Innovent Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Contract liabilities         0 0 $ 3,142,000
Upfront payment received $ 5,000,000            
Collaboration revenue         $ 0 $ 3,400,000  
One-time payment receivable       $ 4,700,000      
Deferred revenue       2,500,000      
Innovent Agreement | Other Income              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
One-time payment receivable       4,700,000      
Innovent Agreement | Maximum              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Potential future sale milestone payments       $ 112,700,000      
Series T Convertible Preferred Stock | Toray Agreement              
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]              
Common stock sold     35,875        
Consideration in excess of fair value     $ 1,500,000        
Allocated from stock purchase agreement     $ 1,500,000